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The role of atopy on cystic ﬁbrosis (CF) progression remains unclear but evidence suggests
that it may inﬂuence the appearance of co-morbid conditions such as CF asthma or allergic
bronchopulmonary aspergillosis (ABPA).
Recognising asthma in patients with CF is not always easy but the identiﬁcation of atopic
markers favours the diagnosis. Physicians should be aware of this fact in order to achieve a
better control of respiratory symptoms in patients with CF.
Bronchial mucosa inﬂammation and abnormal mucus predispose to mould colonisation.
These patients are at higher risk of allergic sensitisation, especially when atopic
susceptibility is present. In the particular case of A. fumigatus, allergic sensitisation
precedes ABPA development, which occurs in up to 10% of CF patients. Progression of lung
function deterioration is most strikingly pronounced in patients with ABPA. Therefore,
sensitisation with A. fumigatus should be regularly tested in patients with CF, especially
those at higher risk.
Recombinant allergens constitute an important advance in differentiating Aspergillus
sensitisation from ABPA itself.
& 2010 SEICAP. Published by Elsevier Espan˜a, S.L. All rights reserved.Background
In the past, several reports have suggested an increased
prevalence of atopy in cystic ﬁbrosis (CF) patients compared
to the general population. This was sustained by an increase
in positive allergy skin prick tests, raised immunoglobulin E
(IgE) and IgE antibodies in these patients.1SEICAP. Published by Elsevier Esp
ail.com (J. Antunes).The major allergic responses in CF patients are to
Aspergillus fumigatus and to a lesser extent, other mould
allergens such as Cladosporium herbarum and Alternaria
alternate.2–4
In more recent studies however, the sensitisation rate to
conventional allergens such as house dust mite and grass
pollen matches the common population.2,5 According to
available data, prevalence of allergy in CF seems to increase
progressively with age as well.1
Historically, Lowe et al. established, in 1949, that 30% of
the relatives of CF patients had a clinical history of allergican˜a, S.L. All rights reserved.
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patients with CF from 16 to 24%.7,8 A Mexican study involving
30 patients with CF showed that 26.6% had respiratory
allergy, diagnosed on clinical and laboratory grounds.9 About
40% had positive skin prick tests to at least one allergen, and
that Aspergillus fumigatus (A. fumigatus) was the most
frequently involved allergen (23% of the cases).9
It is well known that a large number of patients with CF
report symptoms that suggest an allergic type disorder, even
without previous diagnosis of asthma, allergic rhinitis or
eczema.7
The coexistence of respiratory allergy in the form of
bronchial asthma, allergic rhinitis or both is often present in
CF. Recognising these diseases will contribute to a more
global and proper approach of these patients with obvious
improvement in their quality of life.
Although there is great controvery regarding the role
atopy plays in CF, a deep knowledge is required on how the
hypersensitivity phenomenon begins and how the immunoin-
ﬂammatory response vicious circle can be controlled. This
might lead to the development of new lung protection drugs
and, thereafter, prolonged survival in these patients.Cystic ﬁbrosis
Cystic ﬁbrosis (CF) is a well-characterised monogenic
disease; it has an autosomal recessive inheritance pattern
and is caused by a single-gene mutation on the CF
transmembrane conductance regulator (CFTR).10
It is relatively uncommon, although prevalence varies
considerably depending on ethnicity and geography, and
affects preferentially Caucasians of European descent11;
prevalence can reach as many as 1:2500 births among
certain Caucasian groups.12
The molecular mechanisms of the CF mutation have been
well described in previous studies. A strong genotype-
phenotype correlation can be observed. A signiﬁcant aIlelic
heterogeneity exists, resulting in a continuum of disease
expression varying from very mild to very severe. Different
explanations have been proposed for such a wide spectrum
of clinical manifestations.13 These considerations are,
nevertheless, beyond the scope of our review.
Inﬂammation is a cardinal feature of lung disease in CF.
Although the primary genetic defect was detected in CF in
198914 and lung inﬂammation is ubiquitous in CF patients,
we still know very little about how mutations in the CFTR
gene are related to infection and inﬂammation. On the one
hand, abnormal intracellular chloride retention and in-
creased sodium reabsorption contribute to more viscous
secretions which impair the mucociliary clearance. As a
consequence, chronic colonisation by opportunistic patho-
gens, such as Staphylococcus aureus or Pseudomonas
aeruginosa supervenes, leading to persistent inﬂammation
and causing inexorably long-term lung destruction. On the
other hand, lung inﬂammation can also precede lung
infection. Even though the lungs are essentially normal at
the time of birth, several studies have demonstrated
inﬂammation and infectious changes before clinically
evident lung disease is present, even in infancy.15–17
The presence of high neutrophil counts, neutrophil
elastase and inﬂammatory cytokines in broncho-alveolarlavage (BAL) specimens, obstructive mucous plugging and
epithelial metaplasia has been reported, in young children
with CF, even in the absence of positive microbiological
cultures.18 One can still suggest that organisms could be
present in a number too small to appear on sputum cultures
even though they are present in sufﬁcient quantity to trigger
an inﬂammatory response. Nevertheless, once bacterial
clearance is usually reduced when inﬂammation is en-
hanced, the consequences of continuous inﬂammation due
to the primary gene defect could well result in facilitated
colonisation of the CF airways.19,20Cystic ﬁbrosis and asthma
Cystic ﬁbrosis and asthma are not always easily distin-
guished. Wheeze, whether in asthmatic or CF patients,
involves airway mucosal oedema, mechanical obstruction by
accumulated secretions, airway smooth muscle contraction,
and dynamic collapse of airways.
It occurs frequently in both pathologies and for this
reason it is difﬁcult to determine which patients have
concomitant asthma and which wheeze as a result of their
underlying CF lung disease. However, it is important to
readily recognise ‘‘CF asthma’’ once it can contribute to a
better control of respiratory symptoms in patients with CF. It
is clear from the North American Epidemiologic Study of
Cystic Fibrosis (ESCF) that the diagnosis of asthma in CF does
inﬂuence prescribing practice, in particular increasing the
use of inhaled corticosteroids.21,22
There is, however, no consensus on how to deﬁne CF
asthma. Acute airway obstruction reversed by bronchodila-
tors, especially if seasonal or allergen induced, can be a
valuable but fallible indicator, and laboratory data such as
eosinophilia or high IgE levels, are also of limited value, as
explained in later sections.
A personal history (eczema or allergic rhinitis) and a
family history of atopy (including asthma) in ﬁrst degree
relatives are probably the most useful predictors of
asthma.23
Standard spirometric tests, although useful in assessing
lung disease severity, are not reliable tools to diagnose
asthma in CF patients. The reason for this apparent
ineffectiveness of lung function testing in CF patients
suspected of having asthma is the degree of variability in
lung function measures. Forced expiratory volume in one
second and forced vital capacity can vary as much as
15–20%, even when testing on the same day.24,25
Likewise, the role of bronchodilator responsiveness in
patients with CF is not well deﬁned and several studies
report important limitations.26,27 CF patients often show a
degree of bronchodilator responsiveness whether they have
CF asthma or not.28,29
Bronchial hyperresponsiveness (BHR) is a typical ﬁnding
in, but not exclusive to, asthma and even though it is also
found in many CF patients, especially those with poorer lung
function, the underlying mechanism is still debatable.29,30
Even the hypothesised role of atopy in ‘‘CF asthma’’ needs
to be clariﬁed. According to some studies, a strong
association exists between atopy and BHR.31,32 Other
authors, on the contrary, believe it might not be a signiﬁcant
risk factor for BHR development in patients with CF.33–35
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correlate with coexistent asthma, particularly for positive
skin testing patients.31
In a study by Eggleston et al., with CF patients with (20)
and without (16) methacholine hyperreactivity, a signiﬁ-
cantly higher proportion of atopic patients was found in the
ﬁrst group, but no discriminative power between both
groups was found for allergy history.32
On the other hand, several other authors found BHR not
conclusively associated with atopy, even though it is a common
ﬁnding in CF patients.33–35 Mitchell et al. performed methacho-
line challenges in 113 CF patients and found a positive response
in 51% of the cases and asthma in 98% of those. However, there
was no relationship between allergic rhinitis or positive allergen
skin tests and positive methacholine response.33 These ﬁndings
are concordant with other studies, by Sanchez or Valverde-
Molina with 22 and 32 patients, respectively, keeping this
chapter still unﬁnished.34,35
According to Valverde-Molina et al., BHR may be
associated with colonisation or infection with P. aeruginosa
in patients with CF, and this may be a more important risk
factor than atopy.35
Once other causes of serum total IgE elevation are
excluded, particularly allergic bronchopulmonary aspergil-
losis (ABPA), it can also constitute a guide to atopic status,
strengthening the diagnosis of CF asthma in opposition to
‘‘CF wheezers’’ without asthma.36 Atopy can also be
conﬁrmed through positive skin prick testing or serum
speciﬁc IgE tests when common aeroallergens such as house
dust mite, cat, dog, grass and tree pollens, are involved. On
the other hand, as stated by Balfour-Lynn, a reaction to
Aspergillus does not necessarily denote atopy, but this will
be discussed later.23 Nevertheless, a positive result would
still support the diagnosis of CF asthma.37
Asthma and CF differ not only clinically but in terms of
immunopathology as well. In CF, it is mainly neutrophil
driven, whilst in asthma it depends mostly on eosinophils
and lymphocytes, with elevated exhaled nitric oxide levels;
more severe forms of asthma, however, do tend to be
associated with neutrophils.38,39 A Th2 balanced immune
response is strongly characteristic of atopic asthma but, in
general, CF does not quite ﬁt into the Th1/Th2 pattern.39
Patients with chronic Pseudomonas aeruginosa infection and
ABPA also develop predominantly a Th2 type response.40,41
Chronic airway inﬂammation constitutes a determinant
factor for BHR and, despite the similarities between the
inﬂammation found in CF and asthma, immunopathological
mechanisms are considerably different.
In the past, some authors also suggested a common
genetic background linking asthma and CF, suggesting that
atopy in CF patients could result from the same genetic
defect responsible for CF.42 Nevertheless, studies that tried
to assess the association between asthma and CFTR gene
mutations heterozygosity have led to conﬂicting results. In a
study carried out in a Norway, no association was found
between asthma and heterozygous CF.43
A study from 2008 found that, although the relative risk of
asthma did not differ between heterozygous CF and no
heterozygous CF, the values of FEV1, and FEV1/FVC ratio
were lower in carriers, suggesting that, according to
pulmonary function testing, heterozygosity may be related
with a silent obstructive pulmonary proﬁle.44Using 15-year follow-up data from the Copenhagen City
Heart Study, Dahl et al. found that CF DF508 heterozygotes
may be overrepresented among individuals with asthma and
may have poorer lung function than non-carriers. Further-
more, DF508 heterozygosity in context with familial predis-
position to asthma may be associated with a greater annual
FEV1 decline.45
Pathophysiology insights
In this section, the possible relationships between mould
sensitisation, atopy and cystic ﬁbrosis will be revised in a
few words.
Cystic ﬁbrosis patients show several risk factors which
might inﬂuence atopic progression, such as increased
permeability of the bronchial mucosa,46 defective secretory
IgA system47 and entrapment of antigens in infected areas of
the lungs47 in association with ciliar dysfunction.48 This
would result in increased antigenic access through the
tracheobronchial tree, favouring a constant stimulation of
IgE production.
Under normal circumstances, despite high concentrations
of exposure to mould spores, no sensitisation would occur.49
This low sensitisation potential contrasts, however, with
hyphal elements, signiﬁcantly more allergenic. It has been
known that exposure to high concentrations of hyphal
elements, rather than spores, will have a chance of
producing sensitisation. Spores are inhaled into the
bronchial airway, becoming trapped in the luminal
mucus of patients with progressively more severe airway
inﬂammation.
In patients with CF, there will be enough time for spores
to germinate, forming mycelia, with consequent release of
allergenic proteins and sensitisation.50,51 Indeed, it is quite
common to be able to culture Aspergillus fumigatus and
observe hyphal networks in the sputum of CF patients, with
up to 30% having positive cultures.52
The sensitisation process occurs in genetically susceptible
individuals and requires allergen processing by antigen
presenting cells, which then stimulate T cells within the
bronchoalveolar lymphoid tissue (BALT) in a Th2 balanced
way.
Different theories have been proposed concerning the
role of chronic P. aeruginosa colonisation in mould sensitisa-
tion and atopy. The highest IgE levels are associated with
chronic Pseudomonas colonisation and frequent exacerba-
tion of infection. These data have been used to suggest
either that allergy contributes to the lung pathology or,
alternatively, that serious lung infection facilitates allergen
sensitisation.2,53
Aspergillus fumigatus
Special attention should be given to A. fumigatus, the most
prevalent mould allergen identiﬁed in CF patients.2 Coloni-
sation of the lower respiratory tract with A. fumigatus is
particularly frequent in patients with CF, with a reported
incidence of 57%,54 and a prevalence of 40%.55
Aspergillus fumigatus, a widely distributed spore-bearing
fungus, causes multiple diseases in humans,56–58 such as
invasive pulmonary aspergillosis, aspergilloma, and different
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asthma, characterised by a Th2 response59,60; hypersensitiv-
ity pneumonitis, with Th1 response dominance,61 and ABPA,
which will be presented in later sections.
The immune response to A. fumigatus differs in atopic
and non-atopic patients. In the ﬁrst group a Th2 CD4þ T-cell
response and IgE and IgG antibody responses prevail with a
clinical spectrum of allergic sensitivity to ABPA and in non-
atopic patients predominates a Th1 response.60
The most common allergens include A. fumigatus and
Aspergillus clavatus, but other species exist, causing mainly
invasive disease.
Aspergillus has a very small spore size (3–5 mm), which
enables it to penetrate deeply into the lung. Spores are
capable of withstanding extraordinary atmospheric condi-
tions (and suboptimal host defences).62
As mycelia grow, it releases allergens that are processed
by antigen-presenting cells bearing HLA-DR2 or -DR5.
Proteases of A. fumigatus, with elastolytic and collageno-
lytic activities, may play a role facilitating antigen transport
across the epithelial cell layer, by damaging the epithelial
integrity and through direct interaction with epithelial cell
surface receptors, resulting in production of proinﬂamma-
tory cytokines and corresponding inﬂammatory responses.
As previously explained, in susceptible individuals, the
immune response to Aspergillus allergens becomes skewed
toward a Th2 CD4þ cell response.63ABPA
ABPA is a disease primarily occurring in patients with asthma
(1%–2% of asthma patients) or with cystic ﬁbrosis (1%–7.8%
of CF patients).60,64–71
ABPA is a lung disease caused by immediate hypersensi-
tivity reaction against Aspergillus fumigatus. The most
clinically relevant characteristics are impaired mucociliary
clearance, mucoid impactions, wheezing, pulmonary inﬁl-
trates, bronchiectasis and ﬁbrosis.56 Some immunological
manifestations include recurrent episodes of eosinophilic
airways inﬂammation, peripheral blood eosinophilia, in-
creased serum concentrations of IL-2 receptor, high total
serum IgE levels, and increased circulating speciﬁc IgE and
IgG against A. fumigatus antigen.56,72,73
The pathophysiology of ABPA still remains largely spec-
ulative, nonetheless several predisposing factors have been
proposed for ABPA development.
Familial occurrence of ABPA has been reported, suggest-
ing a possible genetic contribution to the disease in CF.74,75
Firstly, Chauhan et al. suggested that Th2 reactivity to a
major Aspergillus fumigatus antigen was restricted by HLA-
DR2 or HLA-DR5 alleles. Later, the same authors concluded
that HLA-DR molecules DR2, DR5, and possibly DR4 or DR7
contribute to susceptibility to ABPA, while HLA-DQ2 appears
to be a protective factor.76 In addition, there may be
increased sensitivity of T cells, B cells, NK cells, and
eosinophils to IL-4 stimulation due to mutations of IL-4R
alpha and/or the Jak/STAT pathway genes.77 The presence
of IL-4R alpha single nucleotide polymorphisms, principally
ile75val, appears to be a genetic risk for the development of
ABPA.78 This suggests a strong immunogenetic susceptibility
in ABPA progression.Likewise, CFTR mutation has also been implicated in the
aetiology of ABPA74 but no signiﬁcant association with any
particular CFTR genotype has been documented.71,79 Miller
et al. found a higher incidence of ABPA among atopic
patients with CF and an increased frequency of hetero-
zygous mutations of the CFTR gene was identiﬁed in this
group.80 Patients with ABPA, but without CF, have been
demonstrated to have higher frequencies of CFTR mutations
as well.80 This could probably be due to abnormal mucus
production with spores trapping in the respiratory mucosa.
Atopy appears to be another important risk factor for
ABPA. ABPA was diagnosed in 22% of atopic individuals with
CF but in only 2% of non-atopic patients.69 In another study,
the majority of patients with ABPA were atopic, as deﬁned
by positive skin prick test to at least one common
aeroallergen, other than A. fumigates.67 Total IgE concen-
tration was found to be increased in A. fumigatus sensitised
patients with CF but with no ABPA.68 All these data
therefore suggest that atopy, especially in CF patients,
may facilitate ABPA development.
Fungal colonisation and mycelia growth in CF has also
been related to increased use of antibiotics for recurrent
bacterial infections, facilitating A. fumigatus sensitisation
and ABPA progression.81
Although previous works detected no association between
ABPA and P. aeruginosa colonisation.82 Nikolaizik et al.
reported a positive correlation between the two entities,
suggesting that P. aeruginosa colonisation favours the
process of A. fumigatus sensitisation.83
The causal relationship between Aspergillus sensitisation
and Pseudomonas colonisation has motivated great discus-
sion over the years as it is difﬁcult to disentangle the
inﬂuences of the Pseudomonas from that of Aspergillus.
In vitro studies report a possible link between Aspergillus
and Pseudomonas, as one of the major allergens of A.
fumigatus is selectively released when Aspergillus is co-
cultured with Pseudomonas. This could explain the in vivo
relationship between colonisation with these two organisms
and the subsequent development of allergy.Allergic sensitisation and clinical relevance
Sensitisation to A. fumigatus can be assessed by skin prick
testing, a cheap, rapid, easy and highly sensitive screening
test with high negative predictive value, or by a serological
battery of assays with high speciﬁcity, but more expensive
and less sensitive.84
Sensitisation to A. fumigatus in CF has been reported to
increase with age and to be as high as 56%.85 When
considering persistent asthma in west European countries,
it is identiﬁed in 20%–25% of patients.66,86,87 In other studies
involving CF, 31–59% of patients were sensitised to A.
fumigates.67,88
When considering CF and ABPA, although sensitisation to
A. fumigatus is crucial to ABPA diagnosis, it is important to
differentiate lung colonisation by Aspergillus (40%),69
allergic sensitisation (20–60%),66,85 and clinically proven
ABPA, a sizeable minority ranging from 1 to 11%.71,89
The evolution from simple sensitisation to ABPA constitu-
tes a crucial phase which urges to be correctly diagnosed in
order to prevent disease progression.
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sensitisation and ‘‘true’’ ABPA differ in terms of speciﬁc IgE
responses to recombinant allergens (rAspf1, rAspf2, rAspf3,
rAspf4 and rAspf6).90
A. fumigatus sensitised asthmatic patients react with
100% speciﬁcity and 88% sensitivity to rAspf1 and rAspf3,
achieving positive and negative predictive values of 100%
and 63% respectively, in terms of A. fumigatus sensitisa-
tion.86 On the other hand, patients with ABPA present
almost exclusively speciﬁc IgE to rAspf4 and rAspf6,
suggesting that speciﬁc IgE to recombinant allergens of A.
fumigatus could help in the early detection of sensitisation
and ABPA itself.86,88 In terms of diagnostic speciﬁcity,
recombinant allergens have proven superior to allergen
extracts.91
However, the relationship between A. fumigatus sensiti-
sation and pulmonary function is still to be clariﬁed. This
issue has been studied by different groups, with conﬂicting
results,68,71,89,92 thus reinforcing the need for adequate
longitudinal studies aimed at establishing the effect of A.
fumigatus sensitisation in the decline of pulmonary func-
tion, particularly in CF patients. Strong evidence exists that
ABPA and bacterial infection or chronic colonisation are
independently linked to a more rapid decline in lung
function. Some authors even suggest that each entity may
inﬂuence differently speciﬁc parameters of lung function
testing but more research is required before any conclusions
are stated.79
Conclusion
In conclusion, strong evidence exists that the atopic status
may inﬂuence the appearance of co-morbid conditions in
patients with CF, such as CF asthma, mould sensitisation and
ABPA.
Cystic ﬁbrosis patients appear to be more prone to mould
sensitisation, in particular to A. fumigatus.
Age, bacterial lung colonisation, genetics and immunol-
ogy appear to be important factors for mould sensitisation.
The relationship between atopy and CF remains under scope
but the immunoallergic evaluation assumes a great interest
for a correct approach of these patients.
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